Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Zag Bio™, Inc.Zag Bio Advances ZAG-101 into Clinical Development for Type 1 DiabetesCAMBRIDGE, Mass., October 05, 2026--Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it has advanced its lead program for Type 1 diabetes (T1D), ZAG-101, into clinical development. The company’s first-in-human Phase 1b/2a clinical trial (LANTERN) will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function.
- Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)Company announcement No. 53 / 2026
- TrinityTrinity's Next Gen Launch Report Shows Pharmaceutical Launches Deliver Strong Performance in the Face of UncertaintyNew research finds 51% of U.S. drug launches exceeded Wall Street revenue expectations in 2025, with oncology products leading the way — Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization,...
- SironaxSironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026Recognized for bold approach to addressing therapeutic targets
- Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.
- Science CorporationScience Corp. Announces Long-Term (36 Months) Results of PRIMA BCI Clinical Trial Showing Durable Vision Restoration in Blind Patients Suffering from Geographic AtrophyALAMEDA, Calif., October 05, 2026--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were presented in a late-breaking session at the 26th EURETINA Congress of European retina specialists in Vienna by Mahi Muqit, MD, PhD, Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and Associate Professor at the Institu
- Anixa Biosciences, Inc.Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialFirst patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 -- Anixa...
- Consano BioConsano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic Clinical data expected in 1H 2027 — Consano Bio, Inc., a clinical-stage biotechnology company...
- SHARxThe Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total SpendingAs GLP-1 and specialty-drug utilization expands, SHARx warns employers that spending control needs forecasting, access strategies and total-spend discipline, not rebate guarantees alone. — A larger rebate does not guarantee lower pharmacy spending,...
- PharmaTher Holdings Ltd.PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINESHighlightsM3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine...
- Forward TherapeuticsForward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 DevelopmentForward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced positive Phase 1 clinical and preclinical data for FT2109, its novel, potential best-in-class oral selective TNFR1 signaling inhibitor. The data are included in two abstracts accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6–11 in Orlando, Florida.
- Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort